A comparison of US, Europe, Japan and India biosimilar regulation

Biosimilars have emerged as a crucial alternative to reference biologics, offering cost-effective treatment options while maintaining comparable efficacy and safety. Regulatory pathways for biosimilars differ across key global markets, including the United State (US), European Union (EU), India and Japan, reflecting distinct approaches to approval, evaluation, and market entry.

The EU a pioneer in biosimilar regulations, established a well- defined approval framework under the European Medicines Agency (EMA), setting global standards. The US Food and Drug Administration (FDA)follows the Biologics Price Competition and Innovation Act (BPCIA), which provides a structured but rigorous pathway for biosmilar approval. India, an emerging biosmilar hub, has developed guidelines that emphasize comparability studies, balancing affordability with regulatory stringency. Japan, under the Pharmaceutical and Medical Devices Agency (PMDA), follow a case-by-case approach, ensuring biosmilars meet high safety and efficacy standards.

This review article compares and contrasts biosimilar regulations across these regions, analyzing approval processes, interchangeability policies, clinical study requirements, and market dynamics. Understanding these regulatory landscapes is essential for global harmonization efforts, facilitating biosimilar access while ensuring patient safety.